Bayer Q1 earnings rise on strong crop science business performance

Bayer reported Q1 EBITDA before special items of 4.45 billion euros, up 9% year over year, with group sales rising 4.1% to 13.41 billion euros. Strong Crop Science performance, including nearly 18% EBITDA growth, offset weaker pharmaceutical profitability, while free cash flow fell to negative 2.32 billion euros due to litigation payments. The company confirmed 2026 guidance and slightly raised reported sales and EBITDA forecasts to reflect FX effects.

Analysis

The key signal is not the quarter itself but the mix shift: crop science is doing the heavy lifting while pharma is increasingly becoming a capital sink. That matters because crop science margins are more cyclical and inventory-sensitive, so the current earnings resilience may be less durable than headline growth suggests if seed/fertilizer demand normalizes or Latin America pricing weakens into the next planting cycle.

The real overhang is legal cash absorption. Negative free cash flow in a period of decent operating performance implies the equity is still funding a multi-year balance sheet repair story, not a clean earnings compounding story. In practice, that caps rerating upside because every incremental dollar of operating improvement is being partially offset by litigation leakage and higher reinvestment, which reduces the probability of a near-term multiple expansion despite better reported guidance.

Competitively, the strongest second-order effect is on peers with cleaner balance sheets and less litigation drag: capital allocators may prefer ag-input names with similar end-market exposure but less legal uncertainty, while pharma peers with stronger patent defensibility should trade as higher-quality substitutes. The market is also likely underestimating FX as a tailwind only at the margin; if the euro weakens further, reported guidance can keep looking better even while underlying cash conversion remains mediocre, creating a potential trap for momentum buyers.

Consensus appears to be anchoring on "cheap after a big run," but the more relevant question is whether the rerating is already pricing in a normalization that may not arrive until litigation and cash flow stabilize. The stock can stay supported for months if crop science remains firm, but the upside from here likely requires either a material litigation de-risking event or evidence that pharma can stop dragging incremental margin. Absent that, the asymmetric trade may be to fade strength rather than chase a lower-quality earnings beat.

Key Decisions for Investors

• Short-dated call spread fade: sell upside exposure in BAYGN via a 1-2 month call spread against the post-earnings strength; thesis is that near-term enthusiasm is front-running cash flow recovery that has not yet materialized.
• Pair trade: long better-quality ag/input exposure, short BAYGN over 3-6 months; use the pair to isolate litigation risk and cash conversion risk while keeping sector beta modest.
• Avoid adding to long-only exposure until there is at least one quarter of positive free cash flow momentum; current reward/risk is poor because operating improvement is being diluted by legal outflows.
• For event-driven accounts, watch for any litigation settlement update or guidance revision over the next 1-2 quarters; only a credible de-risking catalyst is likely to justify a higher multiple from here.